Antidepressant with Novel Mechanism of Action Appears Safe and Effective in Phase 1b Clinical Trial

“Our study finds that this novel compound promotes neurogenesis in a specific part of the brain, is well tolerated and may have robust antidepressant effects. If its efficacy is confirmed in larger trials, this drug could be an important new option for patients not helped by currently available medications.” –Maurizio Fava, MD.

Dr. Fava is the executive director of the Clinical Trials Network and Institute in the Mass General Department of Psychiatry, and the director of the Division of Clinical Research at the Mass General Research Institute.

READ MORE

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s